Sage Therapeutics Inc

Sage Therapeutics — J.P. Morgan Healthcare Conference 2022

30 slides from Sage Therapeutics's conference presentation, Jan 10, 2022

  1. Slide 1: J.P. Morgan Healthcare Conference January 2022

    Slide 1: J.P. Morgan Healthcare Conference January 2022

    J.P. Morgan Healthcare Conference January 2022 Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as “may,” “might,” “will,” “should,” “can,”,“expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “futur

  3. Slide 3: Expertise in brain circuitry; rich pipeline across 3 franchises

    Slide 3: Expertise in brain circuitry; rich pipeline across 3 franchises

    Expertise in brain circuitry Rich pipeline across 3 franchises First and only product approved specifically for postpartum depression 3 late-stage programs 7 clinical phase NCE development programs across 12+ potential indications Strong intellectual property strategy Product platform to drive goals

  4. Slide 4: Patient, economic, societal impact of brain health disorders in the U.S.

    Slide 4: Patient, economic, societal impact of brain health disorders in the U.S.

    Patient, economic, societal impact of brain health disorders in the U.S. demonstrates urgent need for innovation BLS CPI (Consumer Price Index) Calculator was used to estimate 2000 and 2021 economic burden amounts using U.S. specific studies in respect to the indications noted. ~$313B ~$551B Major D

  5. Slide 5: Sage has a leading brain health portfolio

    Slide 5: Sage has a leading brain health portfolio

    COMPOUND PARTNER INDICATIONS PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION MARKETED DEPRESSION FRANCHISE ZULRESSO® (brexanolone) CIV injection Postpartum Depression Zuranolone (SAGE-217) Major Depressive Disorder* Postpartum Depression* Treatment Resistant Depression Generalized Anxiety Disorder

  6. Slide 6: Sage's Mission

    Slide 6: Sage's Mission

    Sage’s Mission: Pioneer solutions to deliver life-changing brain health medicines so every person can thrive

  7. Slide 7: Prevalence and impact continue to increase globally

    Slide 7: Prevalence and impact continue to increase globally

    Prevalence and impact continue to increase globally 62% of MDD respondents in the U.S. were severely impaired by their depression in a survey conducted by the World Health Organization1 Depression has generational impact as well as direct impact on caregivers (e.g., caregivers/ partners unable to wo

  8. Slide 8: Zuranolone clinical data supports potential to fulfill unmet needs in MDD and PPD

    Slide 8: Zuranolone clinical data supports potential to fulfill unmet needs in MDD and PPD

    Zuranolone clinical data supports its potential to fulfill unmet needs for people with MDD and PPD Profile based on data demonstrated in clinical studies with zuranolone to date Note: Success of zuranolone and the product profile depend on the clinical development program and regulatory approval. 1A

  9. Slide 9: Zuranolone has consistently demonstrated rapid improvement in depressive symptoms

    Slide 9: Zuranolone has consistently demonstrated rapid improvement in depressive symptoms

    * -13.6 -17.8 * -10.3 -17.4 -11.2 -12.6 * -12.3 -14.1 † -15.2 -16.0 * -12.5 -9.8 * -9.3 -5.2 -6.7 * -8.3 * -9.8 -6.8 Zuranolone has consistently demonstrated rapid improvement in depressive symptoms in clinical trials ROBIN1 MDD-201B2 MOUNTAIN3 WATERFALL LANDSCAPE (MDD) NEST (PPD) n=74 n=76 n=44 n=4

  10. Slide 10: Zuranolone demonstrated sustained effects in the SHORELINE Study

    Slide 10: Zuranolone demonstrated sustained effects in the SHORELINE Study

    3 Treatment Courses 4 Treatment Courses 5 Treatment Courses 10.3% (n = 15) 6.8% (n = 10) 3.4% (n = 5) 3 Treatment Courses 4 Treatment Courses 5 Treatment Courses 11.9% (n = 58) 10.8% (n = 53) 8.8% (n = 43) Zuranolone demonstrated sustained effects in the SHORELINE Study Patients had the opportunity

  11. Slide 11: Zuranolone demonstrated improvements across domains of quality of life

    Slide 11: Zuranolone demonstrated improvements across domains of quality of life

    Zuranolone demonstrated improvements across domains of quality of life in clinical trials LANDSCAPE and NEST integrated SF-36 patient-reported outcome of functioning and well-being† ~8-12% improvement in physical and general health domains Physical Functioning Role-Physical Bodily Pain General Healt

  12. Slide 12: Continued unmet need in MDD with elevated anxiety

    Slide 12: Continued unmet need in MDD with elevated anxiety

    Continued unmet need evidenced by majority of LANDSCAPE program participants meeting criteria for MDD with elevated anxiety Assessed at baseline by elevated anxiety and somatization symptoms in the setting of MDD (e.g., HAMD-17, HAM-A scales) Improvements in depression and anxiety symptoms observed

  13. Slide 13: Zuranolone has a consistent and differentiated tolerability profile

    Slide 13: Zuranolone has a consistent and differentiated tolerability profile

    Zuranolone has demonstrated a consistent and differentiated tolerability profile in clinical trials “The AEs frequently associated with current antidepressant therapies such as weight gain, sexual dysfunction, euphoria and sleep disruption have not been seen to date with zuranolone. These are the ad

  14. Slide 14: Response vs. discontinuation due to adverse events

    Slide 14: Response vs. discontinuation due to adverse events

    Representative basket of SOC at 8 weeks Response vs. Discontinuation Due to Adverse Events SHORELINE Study STAR*D first line efficacy (Citalopram) Potential benefit-risk profile of zuranolone may be distinct from current antidepressants *Integrated analyses combine doses from ROBIN Study, MDD-201B S

  15. Slide 15: Planned commercialization approach to educate and engage stakeholders

    Slide 15: Planned commercialization approach to educate and engage stakeholders

    Sage’s planned commercialization approach designed to educate and engage stakeholders Stakeholder Needs Strategic Imperatives Patients Rapid, durable therapy without stigmatizing side effects often associated with chronic treatments (e.g., sexual dysfunction/weight gain) Inspire people with MDD and

  16. Slide 16: The MDD landscape presents significant opportunity for a new therapy

    Slide 16: The MDD landscape presents significant opportunity for a new therapy

    The MDD landscape presents significant opportunity for a new therapy to help patients at various points in their treatment journey Numbers represent estimates based on cited data. Sources: 1 Sage Epidemiology Data on File (June 2021), 2 HEOR Truven Claims Analysis 2019-2020- 29% of patients are stab

  17. Slide 17: Potential clinical use scenarios for zuranolone in MDD

    Slide 17: Potential clinical use scenarios for zuranolone in MDD

    Potential clinical use scenarios for zuranolone in MDD “Major depressive disorder with elevated anxiety is a common presentation of depression and is associated with a more prolonged and severe disease course and poor response to current treatments. Data from the LANDSCAPE and NEST clinical developm

  18. Slide 18: Zuranolone development plans: Phase 3 readouts and NDA submissions

    Slide 18: Zuranolone development plans: Phase 3 readouts and NDA submissions

    Zuranolone development plans over next 24 months include two Phase 3 readouts and NDA submissions NDA development and related processes MDD NDA Submission FDA Advisory Committee* DEA Scheduling Ongoing: SHORELINE Initiating: Pediatrics Ph 3b, EAP Medical affairs, health economics, value and access,

  19. Slide 19: Neuropsychiatric disorders: preserving independence through treatment of cognitive impairment

    Slide 19: Neuropsychiatric disorders: preserving independence through treatment of cognitive impairment

    Neuropsychiatric disorders Preserving independence through the treatment of cognitive impairment Globally, disorders involving cognitive dysfunction continue to increase These disorders represent one of the greatest areas of unmet need Significant impact on patients’ ability to work, live independen

  20. Slide 20: SAGE-718 demonstrated improvements in cognitive function in early trials

    Slide 20: SAGE-718 demonstrated improvements in cognitive function in early trials

    SAGE-718 demonstrated improvements in cognitive function in early clinical trials Performance on Executive Tasks in Healthy Volunteers and Patients with Huntington’s, Parkinson’s, and Alzheimer’s Diseases Z-Transformed Change from Baseline to Last Assessment* (Mean ± SE Plotted) *Last assessment at

  21. Slide 21: Huntington's disease is the initial indication for SAGE-718

    Slide 21: Huntington's disease is the initial indication for SAGE-718

    Huntington’s disease is the initial indication for SAGE-718 development Fast Track Designation for SAGE-718 in Huntington’s disease enables interactions to define an efficient potential path to registration in an orphan disease Plans for further development including in Parkinson’s and Alzheimer’s d

  22. Slide 22: SAGE-718 planned clinical development program

    Slide 22: SAGE-718 planned clinical development program

    Abbreviations: HD = Huntington’s Disease, PD = Parkinson’s Disease, AD = Alzheimer’s Disease, PBO = Placebo, PK = Pharmacokinetics, MRI = Magnetic Resonance Imaging SAGE-718 planned clinical development program designed to define potential benefits and leverage learnings CLP-102-B Completed Open-lab

  23. Slide 23: 136.4 million people globally suffer from essential tremor or Parkinson's disease

    Slide 23: 136.4 million people globally suffer from essential tremor or Parkinson's disease

    An estimated 136.4 million people globally suffer from essential tremor (ET) or Parkinson’s disease (PD) Standards of care are inadequate for many people suffering from movement disorders Substantial mental health impact and caregiver burden Movement and neurological disorders Gaps remain in bringin

  24. Slide 24: Improvement in tremor control and ADL score observed in the KINETIC Study

    Slide 24: Improvement in tremor control and ADL score observed in the KINETIC Study

    Baseline Day 8 Day 15 Day 22 Day 29 Day 42 0 -1 -2 -3 LS Mean Change (SE) SAGE-324 (n=33) Placebo (n=34) * * Improvement in tremor control and ADL score observed in the KINETIC Study Change From Baseline for TETRAS Performance Subscale Upper Limb Tremor Total Score in SAGE-324 and Placebo Treatment

  25. Slide 25: 324-ETD-202 Phase 2b dose-response study of SAGE-324

    Slide 25: 324-ETD-202 Phase 2b dose-response study of SAGE-324

    324-ETD-202: Phase 2 double-blind, randomized, placebo-controlled, dose–response study of SAGE-324 for the treatment of patients with essential tremor R Screening Period Up to 28 days Double-Blind Treatment Period (nighttime dosing) Day 1 to 90 Follow-up Period Day 91 to 104 SAGE-324 30mg (n = 40) S

  26. Slide 26: Pairing deep GABA and NMDA domain expertise with neuroactive steroid leadership

    Slide 26: Pairing deep GABA and NMDA domain expertise with neuroactive steroid leadership

    Sage is pairing deep GABA and NMDA domain expertise with leadership in neuroactive steroids >8K compound library and >800 issued patents and patent applications globally Focus on understanding how to modify circuitry that impacts brain function at the network level Robust engine for turning early id

  27. Slide 27: Robust portfolio features NCEs with differentiated target profiles

    Slide 27: Robust portfolio features NCEs with differentiated target profiles

    Sage’s robust portfolio features NCEs with differentiated target profiles that are suited for study across the lifespan ZULRESSO® (brexanolone) CIV zuranolone (Oral) SAGE-324 (Oral) SAGE-718 (Oral) SAGE-421 (Oral) SAGE-319 (Oral) SAGE-904 (Oral) SAGE-689 (Parenteral)

  28. Slide 28: Anticipated 2022 Milestones

    Slide 28: Anticipated 2022 Milestones

    Anticipated 2022 Milestones Early Mid Late *Early:Q1-Q2; Mid:Q2-Q3; Late: Q3-Q4 DEPRESSION FRANCHISE Zuranolone (SAGE-217) l Report topline data from CORAL Study in MDD l l Rolling submission of NDA filing package for the treatment of MDD l Report topline data from SKYLARK Study in PPD l Submit NDA

  29. Slide 29: Sage's goal is to become the leader in brain health

    Slide 29: Sage's goal is to become the leader in brain health

    Sage’s goal is to become the leader in brain health Fearlessly leading the way to create a world with better brain health Data rich 2021 sets up potential for long-term value creation through 2022 and beyond Deep domain expertise paired with neuroactive steroid capability generating the leading brai

  30. Slide 30: Seeing the brain differently makes a world of difference

    Slide 30: Seeing the brain differently makes a world of difference

    Seeing the brain differently makes a world of difference Sage Therapeutes ©2022 90

Source: SEC EDGAR · 8-K filed Jan 10, 2022

More decks from Sage Therapeutics Inc